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Previously we investigated the pharmacokinetic, pharmacodynamic, and pharmacologic properties of all
six sodium-glucose cotransporter (SGLT) 2 inhibitors commercially available in Japan using normal and
diabetic mice. We classiﬁed the SGLT2 inhibitors with respect to duration of action as either long-acting
(ipragliﬂozin and dapagliﬂozin) or intermediate-acting (tofogliﬂozin, canagliﬂozin, empagliﬂozin, and
luseogliﬂozin). In the present study, antidiabetic effects of repeated administration of these SGLT2 in-
hibitors in type 2 diabetic mice were investigated. When repeatedly administered for 4 weeks, all SGLT2
inhibitors signiﬁcantly exhibited antihyperglycemic, antihyperinsulinemic, and pancreas-protective ef-
fects, as well as insulin resistance-improving effects. When compared at doses producing comparable
reduction in hyperglycemia across all drugs, the antidiabetic effects of ipragliﬂozin and dapagliﬂozin
were more potent than those of the other four drugs, but these differences among the six drugs were not
statistically signiﬁcant. Further, an oral glucose tolerance test performed after repeated administration
demonstrated signiﬁcant improvement in glucose tolerance only with ipragliﬂozin and dapagliﬂozin,
implying improved insulin resistance and secretion. Taken together, these ﬁndings demonstrate that,
although all SGLT2 inhibitors exert antidiabetic effects in type 2 diabetic mice, these pharmacologic
effects might be slightly superior with the long-acting drugs, which are able to provide favorable blood
glucose control throughout the day.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Type 2 diabetes is characterized by hyperglycemia and relative
insulin deﬁciency as a result of impaired insulin secretion from
pancreatic b-cells or insulin resistance, and its incidence has
increased dramatically due to increasing prevalence of obesity and
physical inactivity (1,2). In addition, substantial evidence suggests
that chronic hyperglycemia alone can directly impair both insulin
secretion and sensitivity, a phenomenon known as “glucose
toxicity” and which contributes to the progressive worsening of
hyperglycemia (3). Effective glycemic control is therefore important
to prevent both the onset of diabetes and the progressive deterio-
ration of the diabetic disease state. However, while a number ofh, Astellas Pharma Inc., 21
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d/4.0/).antidiabetic drugs are available, maintaining good long-term gly-
cemic control remains difﬁcult in most type 2 diabetic patients,
even when used in combination (4), highlighting the need for
efﬁcient new therapeutic strategies for treating type 2 diabetes.
In recent years, sodium-glucose cotransporter (SGLT) 2 in-
hibitors, which can inhibit reabsorption of ﬁltered glucose in the
kidney and increase urinary glucose excretion, have been devel-
oped and proposed as novel antihyperglycemic agents for treating
type 2 diabetes (5), with several shown to improve hyperglycemia
in this patient population (6). However, while many studies have
focused on nonclinical and clinical pharmacologic effects of SGLT2
inhibitors (7,8), most have examined these drugs on an individual
basis, with only one study comparing several SGLT2 inhibitors in
terms of in vitro inhibitory activity and selectivity for SGLT2 (9) and
none comparing their in vivo pharmacologic effects. In our previous
experiment, we investigated and compared the pharmacokinetic,
pharmacodynamic, and basic pharmacologic properties of all six
SGLT2 inhibitors commercially available in Japan using normal and
diabetic mice (10). We then classiﬁed the SGLT2 inhibitors withnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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dapagliﬂozin) or intermediate-acting (tofogliﬂozin, canagliﬂozin,
empagliﬂozin, and luseogliﬂozin). That study examined single
dosing under free-feeding conditions. In contrast, the present study
was planned to investigate the antidiabetic effects of these SGLT2
inhibitors in type 2 diabetic mice after repeated dosing under
restricted feeding conditions based on these basic data, as well as
parameters including not only hyperglycemia but also pancreatic
insulin content and glucose tolerance.
2. Materials and methods
2.1. Materials
Ipragliﬂozin (11), dapagliﬂozin (12), tofogliﬂozin (13), canagli-
ﬂozin (14), empagliﬂozin (9), and luseogliﬂozin (15) were synthe-
sized at Astellas Pharma Inc. (Ibaraki, Japan) and suspended in 0.5%
methylcellulose solution for oral administration. Doses of drugs are
expressed as the free base form.
2.2. Animals
Male C57BL/6 (normal) and KK/Ay type 2 diabetic mice were
purchased from CLEA Japan at age 6 weeks (Kanagawa, Japan) and
uniformly grouped by blood glucose levels at age 7 weeks. All an-
imals were housed under conventional conditions with controlled
temperature, humidity, and light (12-h lightedark cycle) and were
provided with standard commercial diet and water. Starting from
the day after grouping, animals received feed only during the active
period (i.e. fed for 14-h from 19:00 to 9:00, and fasted for the rest of
the 24-h period), and three days after grouping, drug administra-
tion was started. All animal experimental procedures were
approved by the Institutional Animal Care and Use Committee of
Astellas Pharma Inc. Astellas Pharma Inc., Tsukuba Research Center
has been awarded Accreditation Status by the AAALAC
International.
2.3. Antidiabetic effects of repeated administration of SGLT2
inhibitors
Vehicle or each SGLT2 inhibitor (ipragliﬂozin and dapagliﬂozin:
0.1e1 mg/kg, tofogliﬂozin, canagliﬂozin, empagliﬂozin, and luseo-
gliﬂozin: 1e10 mg/kg) was orally administered to diabetic mice
(and vehicle was orally administered to normal mice) once daily
(just before feeding at night) for 4 weeks. Doses of drugs were set to
produce comparable increase in 24-h urinary glucose excretions
based on the results of our preliminary study. After administration
on Day 1, blood samples (approximately 15 mL) for the evaluation of
blood glucose and plasma insulin levels were obtained from the tail
vein using capillary glass tubes at every 24-h sampling point. Blood
sampling was done during the night (dark period) using a spotlight
to minimize lighting, taking special care not to affect food con-
sumption or related parameters. After drug administration on Day
26, mice were transferred to metabolic cages, and spontaneously
voided urine was collected for 24 h. The morning (5:00e8:00) after
the ﬁnal drug administration (Day 30), blood samples were
collected under nonfasting conditions, and tissues including
pancreas were isolated under isoﬂurane anesthesia.
2.4. Effects of repeated administration of SGLT2 inhibitors on
glucose tolerance
Vehicle or each SGLT2 inhibitor (ipragliﬂozin and dapagliﬂozin:
0.3 mg/kg, tofogliﬂozin, canagliﬂozin, empagliﬂozin, and luseogli-
ﬂozin: 3 mg/kg) was orally administered to diabetic mice once daily(just before feeding at night) for 4 weeks. The ﬁnal administration
(Day 29) was followed by a 2-day withdrawal period, and on the
day after completion of withdrawal, an oral glucose tolerance test
(OGTT) was performed. After mice had fasted during the inactive
period (from 9:00 to 19:00), blood was sampled from a tail vein for
evaluation of fasting blood glucose and plasma insulin levels. The
glucose solution (2 g/kg) was then orally administered, followed by
blood sampling for 2 h.
2.5. Biochemical determinations
Blood and urinary glucose concentrations were measured using
Glucose CII test reagent (Wako Pure Chemical Industries, Ltd.,
Osaka, Japan). Plasma insulin levels were measured using an ultra-
high-sensitivity mouse insulin enzyme-linked immunosorbent
assay (ELISA) kit (Morinaga Institute of Biological Science, Inc.,
Kanagawa, Japan). Hemoglobin A1c (HbA1c) levels were measured
using a DCA2000 System (Bayer Medical, Tokyo, Japan). Pancreatic
hormone levels (insulin, glucagon, and somatostatin) were
measured in accordance with the method previously reported (16).
Plasma ﬁbroblast growth factor 21 (FGF-21), leptin, and adipo-
nectin concentrations were measured using commercial ELISA kits
(R&D Systems Inc., Minneapolis, MN, USA).
2.6. Statistical analysis
The experimental results are expressed as the mean ± standard
error of means (SEM). The areas under the curve (AUCs) and
standard deviation (SD) were calculated from blood glucose and
plasma insulin concentrations measured over time. The Matsuda-
DeFronzo index was calculated using the following formula:
10,000/square root of [(fasting blood glucose  fasting plasma
insulin)  (mean blood glucose  mean plasma insulin during
OGTT)], and disposition index was calculated using the following
formula: (plasma insulin AUC/blood glucose AUC during
OGTT)  Matsuda-DeFronzo index (17). Signiﬁcance of differences
between normal and diabetic vehicle groups was assessed using
Student's t-test, while that between the vehicle- and drug-treated
groups was assessed using one-way ANOVA followed by post-hoc
Tukey's and Dunnett's multiple comparison tests. A value of
P < 0.05 was considered to be signiﬁcant. Statistical and data ana-
lyses were conducted using GraphPad Prism 5 (GraphPad Software,
La Jolla, CA, USA).
3. Results
The 24-h blood sampling study revealed fasting hyperglycemia
in diabetic mice, with increased blood glucose levels after start of
feeding which remained high throughout the 14-h feeding (active)
period compared with normal mice. After the feeding period, blood
glucose levels gradually decreased but still remained high during
the fasting (inactive) period. In association with blood glucose
levels, plasma insulin levels also remained extremely high across
the active and inactive periods. Administration of SGLT2 inhibitors
dose-dependently and signiﬁcantly reduced blood glucose and
plasma insulin levels (Fig. 1 and Fig. 2). The effects of ipragliﬂozin
and dapagliﬂozin on reduction in blood glucose and plasma insulin
levels were evident not only during the active period, but also the
inactive period after administration, showing 24-h persistence. In
contrast, the effects of the other four drugs (tofogliﬂozin, canagli-
ﬂozin, empagliﬂozin, and luseogliﬂozin) on reduction in blood
glucose and plasma insulin levels were potent immediately after
administration but were gradually attenuated from 2 h post-dose,
leading to obvious hyperglycemia and hyperinsulinemia in the
latter half of the active period and throughout the inactive period,
Fig. 1. Antihyperglycemic effects of SGLT2 inhibitors in type 2 diabetic mice. 24-h blood glucose levels were measured on the ﬁrst day of repeated administration for 4-weeks. (A)
Time course of changes in blood glucose levels, (B) the area under the blood glucose concentrationetime curve (AUC), and (C) standard deviation (SD) of blood glucose levels for
24 h. The values are the mean ± SEM for six animals per group. *P < 0.05 vs. normal group, #P < 0.05 vs. diabetic vehicle group.
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Fig. 2. Antihyperinsulinemic effects of SGLT2 inhibitors in type 2 diabetic mice. 24-h plasma insulin levels were measured on the ﬁrst day of repeated administration for 4-weeks.
(A) Time course of changes in plasma insulin levels, (B) the area under the plasma insulin concentrationetime curve (AUC), and (C) standard deviation (SD) of plasma insulin levels
for 24 h. The values are the mean ± SEM for six animals per group. *P < 0.05 vs. normal group, #P < 0.05 vs. diabetic vehicle group.
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ipragliﬂozin and dapagliﬂozin. The SD of blood glucose levels, a
parameter of blood glucose control throughout the day, was also
signiﬁcantly decreased with all drugs, but more markedly with
ipragliﬂozin and dapagliﬂozin, reﬂecting their relatively longer-
acting properties (Fig. 1C). Similarly, variability of plasma insulin
level was also smaller with ipragliﬂozin and dapagliﬂozin,
compared with the other four drugs, with an even larger difference
than that of blood glucose level (Fig. 2C). The 24-h urine sampling
study revealed dose-dependent, signiﬁcant increase in urinary
glucose excretion and associated slight increases in urine volume
with all drugs (Fig. 3). These increases in urinary glucose excretion
were comparable for all drugs at 24 h but varied in persistence: the
effects were signiﬁcant with all drugs until 14 h after administra-
tion (active period) but only remained signiﬁcant in the subsequent
inactive period with ipragliﬂozin and dapagliﬂozin.
After 4-week repeated administration, all SGLT2 inhibitors
dose-dependently and signiﬁcantly reduced nonfasting blood
glucose, HbA1c, and insulin levels and increased pancreatic insulin
content (Fig. 4). No drugs signiﬁcantly affected pancreatic glucagon
or somatostatin content (data not shown). In addition, reductions
in plasma FGF-21 and leptin levels and an increase in plasma adi-
ponectin levels were noted (Fig. 5).Fig. 3. Increase in urinary glucose excretion by SGLT2 inhibitors in type 2 diabetic mice. Urin
excretion (left) and urine volume (right) for (A) 0e7 h, (B) 7e14 h, (C) 14e24 h, and (D) 0e24
#P < 0.05 vs. vehicle group.Although there was no marked and statistically signiﬁcant
differences in these effects among six drugs, comparison at doses
inducing comparable increases in urinary glucose excretion and
reduction in hyperglycemia (ipragliﬂozin and dapagliﬂozin,
0.3 mg/kg; tofogliﬂozin, canagliﬂozin, empagliﬂozin, and luseo-
gliﬂozin, 3 mg/kg) demonstrated the slight superiority of ipragli-
ﬂozin and dapagliﬂozin in controlling daily variability of blood
glucose levels and improvement in diabetic parameters (decrease
in plasma insulin levels, increase in pancreatic insulin content, and
decrease in plasma FGF-21 levels) compared with the other four
drugs (Fig. 6). In addition, decreased plasma leptin levels and
increased plasma adiponectin levels induced by ipragliﬂozin and
dapagliﬂozin were also slightly more potent than with the other
four drugs (Fig. 5).
The OGTT performed after 4-week repeated administration and
subsequent 2-day withdrawal revealed signiﬁcant reductions in
fasting blood glucose and plasma insulin levels and improvement
in glucose tolerance with ipragliﬂozin and dapagliﬂozin, but only a
non-signiﬁcant trend toward improvement with the other four
drugs (Fig. 7). Similarly, Matsuda-DeFronzo and disposition in-
dexes, determined in the test, indicated signiﬁcant improvement or
a trend toward improvement only with ipragliﬂozin and dapagli-
ﬂozin (Fig. 8).e samples were collected for 24 h at Week 4 of repeated administration. Urinary glucose
h. The values are the mean ± SEM for six animals per group. *P < 0.05 vs. normal group,
Fig. 4. Effects of repeated administration of SGLT2 inhibitors on levels of (A) nonfasting blood glucose, (B) HbA1c, (C) plasma insulin, and (D) pancreatic insulin content in type 2
diabetic mice. Each SGLT2 inhibitor was orally administered to diabetic mice for 4 weeks. The values are the mean ± SEM for six animals per group. *P < 0.05 vs. normal group,
#P < 0.05 vs. vehicle group.
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To ensure that the antidiabetic effects observed in our study
reﬂected those in a clinical setting as accurately as possible, daily
feeding timing for diabetic mice was set at 14 h from 19:00 to 9:00,
in reference to the human active period (14 h from 7:00 to 21:00).
This setting allowed diabetic mice to show hyperglycemia due to
feeding in the active period and exhibit reduced blood glucose
levels due to fasting in the inactive period, as well as demonstrate
associated variation in plasma insulin levels, thereby enabling
investigation of daily blood glucose control by SGLT2 inhibitors in a
setting similar to diabetic patients. The 24-h blood and urine
sampling study demonstrated dose-dependent, signiﬁcant effects
of all SGLT2 inhibitors on increase in urinary glucose excretion and
reduction in blood glucose and plasma insulin levels. Since drug
doses were set to produce comparable increases in 24-h urinary
glucose excretion based on results of our preliminary study,
although the effective doses differed, all drugs similarly increased
urinary glucose excretion and reduced hyperglycemia on a daily
basis.
However, duration of action varied; notably, while 24-h
persistent effects were noted with ipragliﬂozin and dapagliﬂozin,
the effects of the other four drugs (tofogliﬂozin, canagliﬂozin,
empagliﬂozin, luseogliﬂozin) were potent immediately after
administration but were gradually attenuated subsequently. This
drop-off in efﬁcacy led to abrogation of increases in urinary glucose
excretion and obvious hyperglycemia and hyperinsulinemia in the
latter half of the feeding (active) period through the fasting (inac-
tive) period. Previously, the persistence of pharmacologic effects of
SGLT2 inhibitors was conﬁrmed to be strongly dependent on their
pharmacokinetics, particularly on their distribution and retention
in the target organ, kidney (10). In addition, the amplitudes of daily
blood glucose and insulin excursions were signiﬁcantly decreased
with all drugs, butmoremarkedly with the long-acting ipragliﬂozin
and dapagliﬂozin. Based on these ﬁndings, the six SGLT2 inhibitors
studied were classiﬁed with respect to duration of action into two
categories: long-acting, comprising ipragliﬂozin and dapagliﬂozin;
and intermediate-acting, comprising tofogliﬂozin, canagliﬂozin,empagliﬂozin, and luseogliﬂozin. Our ﬁndings suggested that the
long-acting SGLT2 inhibitors allow favorable blood glucose control
throughout the day via persistent effects on increasing urinary
glucose excretion and reducing blood glucose and plasma insulin
levels.
Following 4-week repeated administration, all SGLT2 inhibitors
dose-dependently and signiﬁcantly improved hyperglycemia and
hyperinsulinemia and increased pancreatic insulin content, indi-
cating that the effects on reduction in blood glucose and plasma
insulin levels identiﬁed in the 24-h blood sampling study on Day 1
were maintained without being attenuated throughout the 4-week
repeated administration period. Further, these drugs did not
signiﬁcantly affect pancreatic glucagon or somatostatin content,
suggesting that the increase in pancreatic insulin content noted in
the present study was attributable not to the growth of pancreatic
endocrine cells but to the prevention of pancreatic exhaustion by
reduction in plasma insulin levels associated with improvement in
hyperglycemia.
In type 2 diabetic patients, elevated plasma leptin (18) and FGF-
21 (19) levels and reduced plasma adiponectin (20) levels have
been observed and are known to be closely correlated with path-
ogenesis and progression of insulin resistance (21,22). In the pre-
sent study as well, type 2 diabetic mice showed variations in these
adipocyte-derived hormones similar to observations in diabetic
patients, which were reversed with improvement of diabetic con-
ditions by SGLT2 inhibitors, suggesting that SGLT2 inhibitors
improve insulin resistance of type 2 diabetes. Comparison of
pharmacologic effects of these SGLT2 inhibitors at doses producing
comparable increases in urinary glucose excretion and reductions
in hyperglycemia demonstrated a slight but not statistically sig-
niﬁcant superiority of ipragliﬂozin and dapagliﬂozin in the ampli-
tude of daily blood glucose excursion and improvement in diabetic
parameters (hyperinsulinemia, pancreatic exhaustion, and markers
of insulin resistance) compared with the other four drugs. In
addition, other diabetic parameters, including body weight, fat
weight, plasma lipid levels and hepatic lipid contents also exhibited
a similar improvement by drugs without affecting food intake (data
not shown).
Fig. 5. Effects of repeated administration of SGLT2 inhibitors on plasma levels of (A) FGF-21, (B) leptin, and (C) adiponectin in type 2 diabetic mice. Each SGLT2 inhibitor was orally
administered to diabetic mice for 4 weeks. The values are the mean ± SEM for six animals per group. *P < 0.05 vs. normal group, #P < 0.05 vs. vehicle group.
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demonstrated signiﬁcant glucose tolerance improvement only with
ipragliﬂozin and dapagliﬂozin. In the present study, 4-week
repeated administration was followed by 2-day withdrawal, and
after completion of the withdrawal, the effects of increased urinary
glucose excretion by SGLT2 inhibitors were conﬁrmed to have
disappeared before performing the OGTT. The glucose tolerance-
improving effects noted in the present study were therefore
assumed to be attributable not to an acute antihyperglycemic effect
via increased urinary glucose excretion but to improvement in
glucotoxicity due to long-term reduction in hyperglycemia. The
Matsuda-DeFronzo index, a parameter of insulin resistance, and the
disposition index, a parameter of insulin secretion, were also
improved following administration of long-acting SGLT2 inhibitors,
implying improved insulin resistance and secretion. These results
were consistent with the above-mentioned variations in adipocyte-
derived hormones and pancreatic protection induced by SGLT2
inhibitors.
Many epidemiological and interventional studies have
conﬁrmed the association between hyperglycemia and thedevelopment of diabetic symptoms, including glucose intolerance,
insulin resistance, and pancreatic exhaustion, and various compli-
cations such as obesity and nephropathy (23,24). Currently, HbA1c
is considered the gold standard of long-term glycemic control and
is recommended as a routine test in diabetic patients. However,
recent studies have suggested that blood glucose variability
throughout the day, irrespective of the magnitude of hyperglyce-
mia, may confer an additional risk for development of diabetic
micro- and macrovascular complications (25,26). It has been re-
ported that parameters of blood glucose variability, such as mean
amplitude of glucose excursions (MAGEs) and standard deviation of
blood glucose (SDBG), are closely correlated with exacerbation of
inﬂammation/oxidative stress and progression of atherosclerosis in
type 2 diabetic patients (27e29). Thus, better daily control of blood
glucose excursion, which is independent of HbA1c level, is also
important for attenuating progression of diabetic symptoms and
complications. In the present study, while all SGLT2 inhibitors
reduced HbA1c levels comparably, the long-acting SGLT2 inhibitors
were associated with smaller amplitude of daily blood glucose
excursion (SDBG) and were superior in pancreas protection and
Fig. 6. Improvement in various diabetic parameters by repeated administration of SGLT2 inhibitors in type 2 diabetic mice. Effects of SGLT2 inhibitors at mid dose on (A) urinary
glucose excretion, (B) HbA1c level, (C) standard deviation (SD) of blood glucose level for 24 h, (D) plasma insulin level, (E) pancreatic insulin content, and (F) plasma FGF-21 level. The
values are the mean ± SEM for six animals per group. *P < 0.05 vs. normal group, #P < 0.05 vs. vehicle group.
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with the intermediate-acting drugs. These results suggested that
not only long-term blood glucose control, as measured by HbA1c,
but also daily favorable blood glucose control, as measured by
SDBG, and improvement in hyperinsulinemia are crucial for
improving diabetes.
To our knowledge, this is the ﬁrst report comparing and differ-
entiating multiple SGLT2 inhibitors in antidiabetic effects using
mouse model of type 2 diabetes. The present study focused only on
the pancreatic protective effects and the principle causes of type 2
diabetes, such as insulin resistance, and did not include investiga-
tion of other important components in the pathogenesis of type 2
diabetes such as obesity and inﬂammation, or of complications
including nephropathy. Further comprehensive investigation of
these factors is warranted.
The results of the present study provided evidence for superi-
ority of the long-acting SGLT2 inhibitors in antidiabetic effects.
However, concerns with these long-acting SGLT2 inhibitors arenocturia and hypoglycemia due to increased urine volume and
decreased blood glucose levels associated with persistent increase
in urinary glucose excretion. Increased urine volume on adminis-
tration of SGLT2 inhibitors is principally attributable to osmotic
diuresis associated with increased urinary glucose excretion. In the
present study as well, increased urine volumes were noted along
with increased urinary glucose excretions; however, the in-
crements were negligible. The increases in urine volume during the
inactive period (which corresponds to nighttime for humans)
induced by long-acting SGLT2 inhibitors were also not signiﬁcant.
The 24-h blood glucose measurement study showed that the long-
acting SGLT2 inhibitors reduced blood glucose level during the
inactive period but not below the normal blood glucose level, with
no excessive reduction noted. Further, no hypoglycemic symp-
tomsdsuch as excessive weight loss or decreased locomotor acti-
vitydwere noted throughout the study period, nor were any
changes in lipid metabolism including plasma ketone body levels
observed (data not shown). These ﬁndings suggested that long-
Fig. 7. Improvement in glucose tolerance by repeated administration of SGLT2 inhibitors in type 2 diabetic mice. Time course of changes in the (A) blood glucose and (D) plasma
insulin levels, fasting (B) blood glucose and (E) plasma insulin levels, and the area under the (C) blood glucose and (F) plasma insulin concentrationetime curve (AUC) during the
oral glucose tolerance test. The values are the mean ± SEM for six animals per group. *P < 0.05 vs. normal group, #P < 0.05 vs. vehicle group.
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Fig. 8. Improvement in insulin resistance and secretion by repeated administration of SGLT2 inhibitors in type 2 diabetic mice. Indexes of (A) Matsuda-DeFronzo and (B) disposition
were calculated as parameters of insulin resistance and secretion, respectively. The values are the mean ± SEM for six animals per group. *P < 0.05 vs. normal group, #P < 0.05 vs.
vehicle group.
A. Tahara et al. / Journal of Pharmacological Sciences 131 (2016) 198e208 207acting SGLT2 inhibitors are unlikely to cause nocturia or
hypoglycemia.
In conclusion, ﬁndings from the present study provide evidence
that, although all SGLT2 inhibitors studied exert antidiabetic ef-
fects, such as reduction in hyperglycemia through increase in uri-
nary glucose excretion in type 2 diabetic mice, these drugs vary in
terms of the duration of action. Inhibitors are classiﬁedwith respect
to duration of action into two categoriesdlong-acting and inter-
mediate-actingdand the long-acting drugs exert favorable blood
glucose control throughout the day and might be slightly superior
to intermediate-acting drugs in pancreas protection and improve-
ment in insulin resistance and glucose tolerance.
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